DGAP-News: Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors
(firmenpresse) - Astex Pharmaceuticals, Inc.
10.10.2012 12:00
---------------------------------------------------------------------------
DUBLIN, Calif., 2012-10-10 12:00 CEST (GLOBE NEWSWIRE) --
Astex Pharmaceuticals, Inc. (Nasdaq:ASTX), a pharmaceutical company dedicated
to the discovery and development of novel small molecule therapeutics,
announced that Harren Jhoti, PhD, president and director of Astex
Pharmaceuticals, was appointed to the BioIndustry Association (BIA) Board of
Directors.
About Harren Jhoti, PhD
Dr. Harren Jhoti has served as Astex Pharmaceuticals president and member of
the Board of Directors since the company's formation in July 2011. He
co-founded Astex Therapeutics in 1999 and was chief scientific officer until
November 2007 when he was appointed chief executive. Dr. Jhoti was awarded the
Prous Institute-Overton and Meyer Award for New Technologies in Drug Discovery
by the European Federation for Medicinal Chemistry in 2012 and was also named
by the Royal Society of Chemistry as 'Chemistry World Entrepreneur of the Year'
for 2007. He has published widely including in leading journals such as Nature
and Science and has also been featured in TIME magazine after being named by
the World Economic Forum a Technology Pioneer in 2005. Dr. Jhoti served as a
non-executive director of Iconix Inc. Before starting up Astex Therapeutics in
1999, he was head of Structural Biology and Bioinformatics at GlaxoWellcome in
the United Kingdom (1991-1999). Prior to Glaxo, Dr. Jhoti was a post-doctoral
scientist at Oxford University. He received a BSc (Hons) in Biochemistry in
1985 and a PhD in Protein Crystallography from the University of London in
1989.
About BioIndustry Association
Founded over 20 years ago at the infancy of biotechnology, the BioIndustry
Association (BIA) is the trade association for innovative enterprises involved
in UK bioscience. Members include emerging and more established bioscience
companies; pharmaceutical companies; academic, research and philanthropic
organizations; and service providers to the bioscience sector. The BIA
represents the interests of its members to a broad section of stakeholders,
from government and regulators to patient groups and the media. The BIA's goal
is to secure the UK's position as a global hub and as the best location for
innovative research and commercialization, enabling a world-leading research
base to deliver healthcare solutions that can truly make a difference to
people's lives. For further information, please go to www.bioindustry.org
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel
small molecule therapeutics with a focus on oncology. The Company is developing
a proprietary pipeline of novel therapies and is creating de-risked products
for partnership with leading pharmaceutical companies. Astex Pharmaceuticals
co-developed DACOGEN(r) (decitabine) for Injection and receives significant
royalties on global sales from Eisai in North America and from Janssen-Cilag in
the rest of the world.
The Astex Pharmaceuticals, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=12273
For more information about Astex Pharmaceuticals, Inc., please visit
http://www.astx.com.
Forward-Looking Statements
This press release contains 'forward-looking statements' as defined in the
Private Securities Litigation Reform Act of 1995. The reader is cautioned not
to rely on these forward-looking statements. These statements are based on
current expectations of future events. If underlying assumptions prove
inaccurate or unknown risks or uncertainties materialize, actual results could
vary materially from the expectations and projections of Astex Pharmaceuticals
and its marketing partners. Risks and uncertainties include, but are not
limited to, general industry conditions and competition; technological
advances, new products and patents attained by competitors; challenges inherent
in new product development, including obtaining regulatory approvals;
challenges to patents; changes in behavior and spending patterns or financial
distress of purchasers of health care products and services; changes to
governmental laws and regulations and domestic and foreign health care reforms;
trends toward health care cost containment; and increased scrutiny of the
health care industry by government agencies. A further list and description of
these risks, uncertainties and other factors can be found in the Astex
Pharmaceuticals Annual Report on Form 10-K for the fiscal year ended December
31, 2011. Copies of this Form 10-K, as well as subsequent filings, are
available online at www.sec.gov, www.astx.com or on request from Astex
Pharmaceuticals. Astex Pharmaceuticals is not required to update any
forward-looking statements as a result of new information or future events or
developments.
CONTACT: Timothy L. Enns
Astex Pharmaceuticals, Inc.
Senior Vice President
Corporate Communications&Marketing
Tel: +1 (925) 560-2810
E-mail: tim.enns(at)astx.com
Susanna Chau
Astex Pharmaceuticals, Inc.
Manager
Investor Relations
Tel: +1 (925) 560-2845
E-mail: susanna.chau(at)astx.com
Alan Roemer
The Trout Group
Managing Director
Tel: +1 (646) 378-2945
E-mail: aroemer(at)troutgroup.com
Kari Watson
MacDougall Biomedical Communications
Senior Vice President
Tel: +1 (781) 235-3060
E-mail: kwatson(at)macbiocom.com
News Source: NASDAQ OMX
10.10.2012 Dissemination of a Corporate News, transmitted by DGAP -
a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Astex Pharmaceuticals, Inc.
United States
Phone:
Fax:
E-mail:
Internet:
ISIN: US04624B1035
WKN:
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
Themen in dieser Pressemitteilung:
astex-pharmaceuticals-announces-the-appointment-of-president-harren-jhoti
phd-to-the-bioindustry-association-board-of-directors
Unternehmensinformation / Kurzprofil:
Datum: 10.10.2012 - 12:00 Uhr
Sprache: Deutsch
News-ID 191031
Anzahl Zeichen: 6941
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 343 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Astex Pharmaceuticals Announces the Appointment of President Harren Jhoti, PhD to the BioIndustry Association Board of Directors"
steht unter der journalistisch-redaktionellen Verantwortung von
Astex Pharmaceuticals, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
